Developer docs
API playgroundTry for free, no card

Search company profiles

Ixico

Full company profile

uuid0005fev

Namestring
Ixico
Legal namestring
IXICO plc
Websiteurl
ixico.com
Company typeenum
Public
Founded yearint
2004
Descriptiontext

IXICO plc is a London-headquartered, AIM-listed imaging contract research organization (iCRO) specializing in neurological disease clinical trials, with a 20-year operational track record serving global biopharmaceutical companies, biotechs, scientific consortia and non-profits. The company combines clinical trial operations with proprietary AI-enabled neuroimaging technology built around two core assets: the IXI Platform, an AI-driven neuroimaging data management and analysis platform purpose-built for neurological indications, and IXIQ.Ai, a deep-learning brain segmentation engine that has been validated against gold-standard semi-manual methods (such as the Boundary Shift Integral) for measuring brain atrophy in Huntington's, Alzheimer's, Parkinson's and Multiple Sclerosis trials. IXICO's service portfolio includes imaging biomarkers (radiological reads, volumetric MRI, PET/SPECT, advanced MRI techniques such as neuromelanin-sensitive imaging), trial management, data analytics, post-marketing surveillance, and consultancy. The company is pursuing a strategic transition from project-based service contracts toward a 'TechBio' platform-licensing model, including a non-exclusive technology collaboration with Medidata (Dassault Systèmes) integrating IXI with Medidata's clinical trial platform, active participation in consortia such as the Global Alzheimer's Platform Foundation's Bio-Hermes-002 study alongside Sanofi, Biogen, Eli Lilly and Roche, and pursuit of FDA Software-as-Medical-Device approval. Revenue for FY2024-25 was £6.5M (13% YoY growth), with H1 FY2026 revenue of £3.9M (23% YoY growth) and an order book of £18.1M (38% YoY growth) providing strong forward visibility. The company holds ISO/IEC 27001 and ISO 13485 certifications and operates from London with a US subsidiary (IXICO Technologies Inc).

Short descriptiontext

IXICO plc is a London-based, AIM-listed imaging contract research organization (iCRO) that provides AI-enabled neuroimaging and biomarker analytics services to global biopharma and biotech companies conducting clinical trials in Alzheimer's, Huntington's, Parkinson's and other neurological diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial imaging, neuroimaging analytics, biomarker analysis, neurological disease research, imaging contract research
Industry3 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHDAAAEAH
Medical Imaging AI
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Clinical Trial Neuroimaging Analytics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical Trial Imaging Services
TypeProfessional Services
Description

IXICO generates revenue by providing neuroimaging and biomarker analytics services to biopharma companies conducting clinical trials in neurological disorders. Revenue is derived from project-based service contracts for imaging analysis, trial management, and consultancy services. H1 2026 revenues of £3.9 million represent 23% growth, driven by new contract wins, contract extensions with existing clients, increased biomarker analysis activity, and expansion into later-stage clinical trials.

ukinvestormagazine.co.uk
2Platform Licensing (Strategic Transition)
TypeSubscription Recurring
Description

IXICO is executing a strategic transition from service-based contract model to a proprietary AI platform, licensing its IXI platform to biopharma clients for recurring revenue streams. The goal is to shift from project-based service contracts to a scalable TechBio model where clients license the platform. This includes pursuing FDA approval as a software medical device.

bitget.com
3Blood-Based Biomarker Services
TypeProfessional Services
Description

Revenue from blood-based biomarker contracts, including new contract wins and extensions. Examples include £1.2 million total contract win and extension for blood-based biomarker work.

bitget.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1IXI Platform
Description

AI-enabled neuroimaging technology platform for precision medicine, purpose-built to drive clinical trial imaging and biomarker science insights in neurological disease research.

ixico.com
+1 more record
Core offering1 text field

IXICO provides AI-enabled neuroimaging and biomarker analytics for clinical trials in neurological diseases. Its proprietary IXI Platform uses deep learning to automate MRI and PET scan analysis (brain atrophy, amyloid detection, hippocampal subfield segmentation) for Alzheimer's, Huntington's, Parkinson's, and Multiple Sclerosis trials. The company operates as an imaging Contract Research Organisation (iCRO), combining the platform with expert clinical trial operations, radiological reads, trial management, and consultancy services for biopharma clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • AI platform sensitivity highest among tested methods for detecting whole brain and caudate volume loss in Huntington's disease studies
+4 more records
Product overview1 text field

Ixico operates as a global neuroscience imaging and biomarker analytics company offering an integrated platform-plus-services model. At its core is the IXI Platform, a proprietary AI-enabled neuroimaging technology platform purpose-built for precision medicine in neurological disease clinical trials. The IXI Platform is complemented by IXIQ.Ai, IXICO's deep learning-based brain segmentation technology. Together, these form the technological foundation that powers Ixico's service offerings, which include Imaging Biomarkers (radiological reads, volumetric MRI, PET & SPECT, advanced MRI), Trial Management, Data Analytics, Post-Marketing Surveillance, and Consultancy services. The company serves pharmaceutical and biotech clients across Alzheimer's disease, Huntington's disease, Parkinson's disease, Multiple Sclerosis, and other rare neurological diseases. Ixico also licenses its platform through strategic partnerships such as the Medidata collaboration to generate recurring revenue streams.

Product and service6 records
1IXI Platform
CategoryCore platform
Description

Proprietary, AI-enabled neuroimaging technology platform for precision medicine, purpose-built to drive clinical trial imaging and biomarker science insights in neurological disease research. Manages global clinical trial data, precisely reads radiological scans, and measures key imaging biomarkers linked to the identification, progression, and treatment of neurological conditions.

2Imaging Biomarkers Services
CategoryClinical trial services
Description

Comprehensive imaging biomarker services including radiological reads, volumetric MRI analysis, PET and SPECT imaging, and advanced MRI techniques (neuromelanin-sensitive MRI, free water imaging, diffusion tensor imaging) for neurological disease clinical trials.

3Trial Management Services
CategoryClinical trial services
Description

Clinical trial management services supporting the design, execution, and oversight of neuroimaging-focused clinical trials, including site management, reader qualification, and regulatory compliance support.

4Data Analytics Services
CategoryClinical trial services
Description

Data analytics services for clinical trial imaging data, including centralised image reading, data standardisation, statistical analysis, and biomarker endpoint selection for neurological disease trials.

5Post-Marketing Surveillance Services
CategoryClinical trial services
Description

Post-marketing surveillance services for monitoring drug safety and efficacy in real-world neurological disease populations using imaging biomarkers.

6Consultancy Services
CategoryConsulting services
Description

Expert consultancy services in neuroimaging, biomarker strategy, clinical trial design, and regulatory affairs for neurological disease drug development programmes.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

Strategic collaboration as partner in Bio-Hermes-002 study, an observational platform evaluating blood-based and digital biomarkers for improving prediction, detection, and diagnosis of Alzheimer's disease. GAP is a non-profit foundation working to reduce the time and cost of Alzheimer's clinical trials. Data from the study is hosted on AD Workbench platform managed by Gates Ventures Alzheimer's Disease Data Initiative.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

Joined as new partner in Bio-Hermes-002 study, analyzing additional biomarkers to augment the study's existing database alongside existing partners Biogen, Eli Lilly, Roche, and others.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

Existing partner in Global Alzheimer's Platform Foundation's Bio-Hermes-002 observational study evaluating blood-based and digital biomarkers for Alzheimer's disease.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

Existing partner in Global Alzheimer's Platform Foundation's Bio-Hermes-002 observational study for Alzheimer's disease biomarkers.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

Existing partner in Global Alzheimer's Platform Foundation's Bio-Hermes-002 observational study. Roche is also involved in neuromelanin MRI research through the Prasinezumab program.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-26
Description

Non-exclusive technology collaboration aligning IXI Platform with Medidata's clinical trial platform to create a unified neuroimaging data and analysis offering for biopharma clinical trials. Medidata serves 18 of top 25 pharma companies and 90% of global CROs across 140 geographies. The collaboration provides IXICO with expanded scale, technological co-development opportunities, market reach, and an additional commercial route.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-23
Description

IXICO supporting the Global Alzheimer's Platform Foundation's Bio-Hermes 2 trial, an observational study evaluating blood-based and digital biomarkers alongside imaging for Alzheimer's disease.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-04-15
Description

Collaboration agreement focused on advancing neuroimaging capabilities for clinical trials in neurological diseases.

9Huntington's Disease Image Harmonization Consortium (HD-IH)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-12
Description

Consortium using IXICO's IXIQ.Ai technology to conduct large-scale analysis of brain changes in Huntington's disease. Consortium secured new member and additional funding to complete analysis, further validating IXICO's AI imaging platform.

ixico.com
10Top 5 Global CRO (Unnamed)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-02-14
Description

New imaging master vendor agreement with a top 5 global CRO, providing first contract award for IXIQ.Ai brain imaging technology. This partnership was described as a significant milestone for commercial expansion.

ixico.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ixico

Clinical Trial Neuroimaging Analyticsixico.com

IXICO plc is a London-based, AIM-listed imaging contract research organization (iCRO) that provides AI-enabled neuroimaging and biomarker analytics services to global biopharma and biotech companies conducting clinical trials in Alzheimer's, Huntington's, Parkinson's and other neurological diseases.

What Ixico does

IXICO plc is a London-headquartered, AIM-listed imaging contract research organization (iCRO) specializing in neurological disease clinical trials, with a 20-year operational track record serving global biopharmaceutical companies, biotechs, scientific consortia and non-profits. The company combines clinical trial operations with proprietary AI-enabled neuroimaging technology built around two core assets: the IXI Platform, an AI-driven neuroimaging data management and analysis platform purpose-built for neurological indications, and IXIQ.Ai, a deep-learning brain segmentation engine that has been validated against gold-standard semi-manual methods (such as the Boundary Shift Integral) for measuring brain atrophy in Huntington's, Alzheimer's, Parkinson's and Multiple Sclerosis trials. IXICO's service portfolio includes imaging biomarkers (radiological reads, volumetric MRI, PET/SPECT, advanced MRI techniques such as neuromelanin-sensitive imaging), trial management, data analytics, post-marketing surveillance, and consultancy. The company is pursuing a strategic transition from project-based service contracts toward a 'TechBio' platform-licensing model, including a non-exclusive technology collaboration with Medidata (Dassault Systèmes) integrating IXI with Medidata's clinical trial platform, active participation in consortia such as the Global Alzheimer's Platform Foundation's Bio-Hermes-002 study alongside Sanofi, Biogen, Eli Lilly and Roche, and pursuit of FDA Software-as-Medical-Device approval. Revenue for FY2024-25 was £6.5M (13% YoY growth), with H1 FY2026 revenue of £3.9M (23% YoY growth) and an order book of £18.1M (38% YoY growth) providing strong forward visibility. The company holds ISO/IEC 27001 and ISO 13485 certifications and operates from London with a US subsidiary (IXICO Technologies Inc).

Ixico firmographics

Firmographics
Name
Ixico
Legal name
IXICO plc
Website
https://ixico.com
Company type
Public
Founded year
2004
Operating status
Operating
Headcount range
51–100 employees
Short description
IXICO plc is a London-based, AIM-listed imaging contract research organization (iCRO) that provides AI-enabled neuroimaging and biomarker analytics services to global biopharma and biotech companies conducting clinical trials in Alzheimer's, Huntington's, Parkinson's and other neurological diseases.
Ownership category
akta.pro rank

Ixico industry classification

Industry
Product category
Clinical Trial Neuroimaging Analytics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHDAAAEAH
Medical Imaging AI

Keywords

  • Clinical trial imaging
  • Neuroimaging analytics
  • Biomarker analysis
  • Neurological disease research
  • Imaging contract research

Where Ixico is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Ixico business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Clinical Trial Imaging Services: IXICO generates revenue by providing neuroimaging and biomarker analytics services to biopharma companies conducting clinical trials in neurological disorders. Revenue is derived from project-based service contracts for imaging analysis, trial management, and consultancy services. H1 2026 revenues of £3.9 million represent 23% growth, driven by new contract wins, contract extensions with existing clients, increased biomarker analysis activity, and expansion into later-stage clinical trials.
  2. Platform Licensing (Strategic Transition): IXICO is executing a strategic transition from service-based contract model to a proprietary AI platform, licensing its IXI platform to biopharma clients for recurring revenue streams. The goal is to shift from project-based service contracts to a scalable TechBio model where clients license the platform. This includes pursuing FDA approval as a software medical device.
  3. Blood-Based Biomarker Services: Revenue from blood-based biomarker contracts, including new contract wins and extensions. Examples include £1.2 million total contract win and extension for blood-based biomarker work.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels9 records

Ixico product offering

Product offering

Core offering

IXICO provides AI-enabled neuroimaging and biomarker analytics for clinical trials in neurological diseases. Its proprietary IXI Platform uses deep learning to automate MRI and PET scan analysis (brain atrophy, amyloid detection, hippocampal subfield segmentation) for Alzheimer's, Huntington's, Parkinson's, and Multiple Sclerosis trials. The company operates as an imaging Contract Research Organisation (iCRO), combining the platform with expert clinical trial operations, radiological reads, trial management, and consultancy services for biopharma clients.

Product overview

Ixico operates as a global neuroscience imaging and biomarker analytics company offering an integrated platform-plus-services model. At its core is the IXI Platform, a proprietary AI-enabled neuroimaging technology platform purpose-built for precision medicine in neurological disease clinical trials. The IXI Platform is complemented by IXIQ.Ai, IXICO's deep learning-based brain segmentation technology. Together, these form the technological foundation that powers Ixico's service offerings, which include Imaging Biomarkers (radiological reads, volumetric MRI, PET & SPECT, advanced MRI), Trial Management, Data Analytics, Post-Marketing Surveillance, and Consultancy services. The company serves pharmaceutical and biotech clients across Alzheimer's disease, Huntington's disease, Parkinson's disease, Multiple Sclerosis, and other rare neurological diseases. Ixico also licenses its platform through strategic partnerships such as the Medidata collaboration to generate recurring revenue streams.

Differentiator

Problem solved

Functional benefit

Brands

  • IXI Platform: AI-enabled neuroimaging technology platform for precision medicine, purpose-built to drive clinical trial imaging and biomarker science insights in neurological disease research.
  • IXIQ.Ai

Products and services

  • IXI Platform Proprietary, AI-enabled neuroimaging technology platform for precision medicine, purpose-built to drive clinical trial imaging and biomarker science insights in neurological disease research. Manages global clinical trial data, precisely reads radiological scans, and measures key imaging biomarkers linked to the identification, progression, and treatment of neurological conditions.
  • Imaging Biomarkers Services Comprehensive imaging biomarker services including radiological reads, volumetric MRI analysis, PET and SPECT imaging, and advanced MRI techniques (neuromelanin-sensitive MRI, free water imaging, diffusion tensor imaging) for neurological disease clinical trials.
  • Trial Management Services Clinical trial management services supporting the design, execution, and oversight of neuroimaging-focused clinical trials, including site management, reader qualification, and regulatory compliance support.
  • Data Analytics Services Data analytics services for clinical trial imaging data, including centralised image reading, data standardisation, statistical analysis, and biomarker endpoint selection for neurological disease trials.
  • Post-Marketing Surveillance Services Post-marketing surveillance services for monitoring drug safety and efficacy in real-world neurological disease populations using imaging biomarkers.
  • Consultancy Services Expert consultancy services in neuroimaging, biomarker strategy, clinical trial design, and regulatory affairs for neurological disease drug development programmes.

Quantifiable outcome

  • AI platform sensitivity highest among tested methods for detecting whole brain and caudate volume loss in Huntington's disease studies
  • +4 more outcomes

Companies that use Ixico

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles1 record

Ixico technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability10 records

Feature6 records

Ixico partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • Global Alzheimer's Platform Foundation (GAP)coreStrategic or Co-development Partner · 18 May 2026Strategic collaboration as partner in Bio-Hermes-002 study, an observational platform evaluating blood-based and digital biomarkers for improving prediction, detection, and diagnosis of Alzheimer's disease. GAP is a non-profit foundation working to reduce the time and cost of Alzheimer's clinical trials. Data from the study is hosted on AD Workbench platform managed by Gates Ventures Alzheimer's Disease Data Initiative.
  • SanofiminorStrategic or Co-development Partner · 18 May 2026Joined as new partner in Bio-Hermes-002 study, analyzing additional biomarkers to augment the study's existing database alongside existing partners Biogen, Eli Lilly, Roche, and others.
  • BiogenminorStrategic or Co-development Partner · 18 May 2026Existing partner in Global Alzheimer's Platform Foundation's Bio-Hermes-002 observational study evaluating blood-based and digital biomarkers for Alzheimer's disease.
  • Eli Lilly and CompanyminorStrategic or Co-development Partner · 18 May 2026Existing partner in Global Alzheimer's Platform Foundation's Bio-Hermes-002 observational study for Alzheimer's disease biomarkers.
  • RocheminorStrategic or Co-development Partner · 18 May 2026Existing partner in Global Alzheimer's Platform Foundation's Bio-Hermes-002 observational study. Roche is also involved in neuromelanin MRI research through the Prasinezumab program.
  • Medidata (Dassault Systèmes)coreTechnology or Integration · 26 March 2026Non-exclusive technology collaboration aligning IXI Platform with Medidata's clinical trial platform to create a unified neuroimaging data and analysis offering for biopharma clinical trials. Medidata serves 18 of top 25 pharma companies and 90% of global CROs across 140 geographies. The collaboration provides IXICO with expanded scale, technological co-development opportunities, market reach, and an additional commercial route.
  • Global Alzheimer's Platform Foundation (GAP) - Bio-Hermes 2 TrialcoreStrategic or Co-development Partner · 23 May 2024IXICO supporting the Global Alzheimer's Platform Foundation's Bio-Hermes 2 trial, an observational study evaluating blood-based and digital biomarkers alongside imaging for Alzheimer's disease.
  • Life Molecular ImagingminorStrategic or Co-development Partner · 15 April 2024Collaboration agreement focused on advancing neuroimaging capabilities for clinical trials in neurological diseases.
  • Huntington's Disease Image Harmonization Consortium (HD-IH)coreStrategic or Co-development Partner · 12 July 2023Consortium using IXICO's IXIQ.Ai technology to conduct large-scale analysis of brain changes in Huntington's disease. Consortium secured new member and additional funding to complete analysis, further validating IXICO's AI imaging platform.
  • Top 5 Global CRO (Unnamed)coreChannel Partner/ Reseller/ Distributor · 14 February 2022New imaging master vendor agreement with a top 5 global CRO, providing first contract award for IXIQ.Ai brain imaging technology. This partnership was described as a significant milestone for commercial expansion.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Ixico competitors and assessment

Company assessment

Market position

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Ixico social profiles

Digital presence

Ixico compliance and trust

Trust signal

Compliance2 records

Ixico financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ixico leadership team

Management profile

Number of profiles

Profiles8 records

Ixico subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Ixico funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ixico M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ixico

What does Ixico do?

IXICO provides AI-enabled neuroimaging and biomarker analytics for clinical trials in neurological diseases. Its proprietary IXI Platform uses deep learning to automate MRI and PET scan analysis (brain atrophy, amyloid detection, hippocampal subfield segmentation) for Alzheimer's, Huntington's, Parkinson's, and Multiple Sclerosis trials. The company operates as an imaging Contract Research Organisation (iCRO), combining the platform with expert clinical trial operations, radiological reads, trial management, and consultancy services for biopharma clients.

Is Ixico a public or private company?

Ixico is a public company. It is classified as public and is currently operating.

When was Ixico founded?

Ixico was founded in 2004. It employs 51 to 100 people.

Where is Ixico based?

Ixico is headquartered in London, United Kingdom, in the Europe region.

How does Ixico make money?

Three revenue lines are on record. Clinical Trial Imaging Services are the primary driver. The others are platform Licensing (Strategic Transition) and blood-Based Biomarker Services.

Does Ixico have an API?

No public API is recorded for Ixico.

What industry is Ixico in?

Ixico's product category is Clinical Trial Neuroimaging Analytics. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 621511 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
UK Investor MagazineIXICO unveils AI tool to detect brain microbleeds in Alzheimer’s scansIXICO unveiled an AI tool at an Alzheimer's clinical-trials conference to detect cerebral microbleeds on MRI scans. The two-stage system detected about 90% of microbleeds, addressing variability in manual review. The announcement is research-only, with no commercial contract or short-term revenue.TradingViewRCS - IXICO plc - New Alzheimer's AI ToolIXICO presented new research at CTAD 2026 on an AI tool that helps radiologists detect cerebral microbleeds on MRI scans. The tool detected about 90% of microbleeds per scan, performing consistently across studies and imaging techniques. The company says this improves efficiency and accuracy in monitoring patient safety for anti-amyloid therapies.UK Investor MagazineIXICO wins £2.7m Huntington’s disease trial contractIXICO announced a £2.7m contract to provide imaging analysis for a late-stage Huntington's disease drug trial, with revenue expected over six years. The neuroscience imaging company's shares rose 17% on the news, following two Alzheimer's contract awards.ProactiveinvestorsIXICO wins £2.7m Huntington’s disease trial contractIXICO PLC secured a £2.7 million contract to provide imaging and biomarker services for a global phase 3 Huntington's disease trial. The six-year agreement is expected to generate £2.7 million in revenue and marks the second phase 3 contract in the condition in 12 months.YahooIXICO research challenges assumption that cutting scanner variability always improves Huntington's trackingIXICO presented research at the European Huntington's Disease Network Clinical Research Congress 2026 showing that reducing MRI scanner variability does not always improve Huntington's disease tracking. The study tested a method to strip unwanted variation in brain volume measurements, stressing the need to validate imaging analysis methods and preserve clinically relevant information.AdvfnIXICO plc Alzheimer's contract winsIXICO announced two Alzheimer's disease contracts totaling about £1.5 million, including a Phase 2b trial management contract and a contract extension. The wins follow a FY26 trading update that reported 28% revenue growth, and the contracts are expected to be recognized over one to three years.Yahoo3 British AI Healthcare Stocks With Revenue Up To £61 BillionThree British AI healthcare stocks—Haleon, IXICO, and AstraZeneca—are profiled, with Haleon generating £4.7b from EMEA and Latin America, IXICO £7m, and AstraZeneca US$61.4b. Haleon's AI push may affect margins and growth, while AstraZeneca's oncology AI work could shift economics of a major cancer indication.YahooIXICO presents Parkinson's research showing improved brain imaging contrastIXICO presented research at a European MRI conference showing magnetisation transfer gradient echo (MT-GRE) provides better contrast than turbo spin echo (TSE) for imaging the substantia nigra in Parkinson's disease. The study found MT-GRE gave superior contrast between the region and surrounding tissue, and IXICO also introduced a new method to measure changes without precise outlining. Further research will test whether MT-GRE can distinguish patient groups and track disease changes.Yahoo3 British AI Stocks With Revenue Up To £61 BillionThree UK AI healthcare stocks—Haleon, IXICO, and AstraZeneca—are profiled, with Haleon generating £3.8b in North America and AstraZeneca $61.4b in revenue. Haleon's Microsoft AI collaboration and AstraZeneca's AI oncology focus are highlighted, while IXICO remains loss-making. The article notes that future earnings depend on cost pressures and AI-driven efficiency.BioWorldIxico sees imaging driving precision medicine in neurologyIxico CEO Bram Goorden said AI imaging platforms are transforming neurology by identifying biomarkers for earlier, more accurate diagnoses of neurodegenerative diseases. He noted these technologies pave the way for targeted therapies, contrasting with neurology's past lack of clarity.